Skip Ribbon Commands
Skip to main content
CIBMTR

News Releases

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   /   Reference Center   /   News Releases
  • Print
  • Share

 News Releases

Stay up-to-date on the latest news from the CIBMTR.


Recent News

Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

September 11, 2019: Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced the entry into a research agreement to collect and analyze health outcomes data in patients with hematologic malignancies who receive an allogeneic hematopoietic stem cell transplant (HSCT, or bone marrow transplant) from various donor sources. The CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide. 


CIBMTR to Track Long-Term Outcomes Data for Kymriah®

September 14, 2018: A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T-cell (CAR-T) therapies has been established between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Novartis. Under the terms of the collaboration, CIBMTR will collect long-term safety and efficacy data from patients (pediatrics and adults) treated with Kymriah® (tisagenlecleucel) who agree to participate in the CIBMTR registry for cellular therapy.


CIBMTR Announces Collaboration with Kite to Track Long-Term Outcomes Data for YESCARTA®

May 17, 2018: A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies is formed between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Kite, a Gilead Company. CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide. Under the terms of the agreement, CIBMTR will collect and analyze long-term safety and efficacy data for YESCARTA® in a commercial setting.









Last Updated: 9/11/2019 8:38 AM
CIBMTR